Kwality Pharmaceuticals informs about updates

26 Nov 2024 Evaluate
Kwality Pharmaceutical has announced that they have successfully received domestic and export product approvals for the manufacturing and sale of its biological product, PEGylatedAsparaginase. This significant milestone underscores its commitment to delivering high-quality therapeutic solutions and marks an important step forward, as it is first product from the biologics portfolio to be commercialized in both domestic and export markets. L-Asparaginase is an E. coli-derived enzyme primarily used in the treatment of acute lymphoblastic leukemia (ALL). The PEGylation process enhances the stability of the molecule and reduces the risk of allergic reactions, thereby improving patient outcomes and treatment efficacy. Furthermore, Kwality Pharmaceutical is actively engaged in discussions with leading domestic B2B companies to offer our PEGylated-Asparaginase on a CDMO (Contract Development and Manufacturing Organization) basis. These collaborations aim to leverage our manufacturing expertise, ensuring wider availability of this critical therapy. This approach not only strengthens local partnerships but also enhances patient access across various regions.

The above information is a part of company’s filings submitted to BSE.

Kwality Pharma Share Price

907.30 -6.60 (-0.72%)
28-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1735.15
Dr. Reddys Lab 1192.65
Cipla 1492.85
Lupin 1998.85
Zydus Lifesciences 948.35
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.